When reports of rare but severe blood clots emerged after Johnson & Johnson’s COVID vaccine, they threatened to overshadow an otherwise successful immunization campaign and left scientists searching for an explanation. Researchers now say they have traced many of those events to a specific immune reaction tied to an unusual antibody that attacks the body’s own platelets. The new work suggests the issue was not the entire vaccine platform, but a very particular misfire in the way some people’s immune systems built that antibody.
The condition, known as vaccine-induced immune thrombotic thrombocytopenia, or VITT, combines dangerous clotting with a drop in platelets and appeared after adenovirus-based shots like Johnson & Johnson’s. For years, the mechanism behind VITT was unclear, complicating risk communication and vaccine design. By dissecting the structure and genetic sequence of the antibody that drives VITT, scientists now argue they can explain how clotting can follow an adenovirus vaccine and why it struck only a tiny fraction of recipients, estimated at about 1 case per 100,000 to 250,000 doses in some early reports.
From mystery clots to a genetic trigger
VITT was first recognized as a distinct syndrome because patients developed clots in unusual places, such as veins in the brain, along with low platelet counts and antibodies against a protein called platelet factor 4. What no one could explain at first was why a COVID shot, rather than a classic infection or a blood thinner like heparin, would set off that chain reaction. Early case reports pointed to the presence of anti–platelet factor 4 antibodies, but they did not show what made these antibodies so dangerous or how they arose in the first place.
That gap started to close when scientists carried out a deep structural analysis of the antibody that causes VITT. In the new work, researchers performed a detailed study of the antibody’s shape and then deduced the genetic sequence responsible for its harmful behavior. By reading the DNA instructions that B cells used to build this antibody, they could point to a specific genetic trigger behind vaccine-related blood clots, instead of a vague “bad reaction.” In a set of 698 analyzed antibody sequences, a striking pattern appeared, suggesting that many VITT cases shared the same basic blueprint.
What the VITT antibody looks like
The structure of an antibody is not just a static shape; it reflects how the immune system has learned to recognize a target. In VITT, the antibody binds tightly to platelet factor 4, forming complexes that can activate platelets and spark clot formation. By examining the three-dimensional arrangement of the antibody’s binding regions, the research team showed that this VITT antibody is unusually well suited to latch onto platelet factor 4 in a way that mimics the body’s own immune defenses gone wrong. That structural match helps explain why, once formed, the antibody can cause dramatic clotting even when only small amounts are circulating in the blood.
Crucially, the scientists did not stop at shape. They traced the antibody back to its genetic roots, identifying a shared genetic sequence that appeared across VITT cases. This sequence acts like a blueprint for the harmful antibody, suggesting that a narrow set of B cells, all using similar DNA instructions, are responsible. In one analysis, a particular gene segment appeared in 71,977 separate reads, a strong sign that a small group of B cells had expanded rapidly. The researchers said the antibody’s structure allowed it to mimic a normal immune response, but in a distorted way that targets platelet factor 4 instead of an invading virus, turning a protective response into a self-inflicted attack.
Linking antibodies to their parent immune cells
Once the antibody’s genetic code was in hand, scientists could work backward to the immune cells that produced it. Antibody molecules carry subtle signatures that point back to the B cells that made them, much like handwriting can reveal the writer. Those antibody molecules offered clues about which immune cell clones expanded during VITT, allowing researchers to reconstruct how the response unfolded over time and how quickly it might ramp up after exposure to an adenovirus-based vaccine.
Using those clues, the team was able to link the immune cells responsible for VITT across different patients. According to one analysis, the scientists could connect the immune that produced the VITT antibodies and show that they shared common features, including repeated use of the same light-chain gene family. That finding suggests VITT is not a random mix of immune errors but a repeatable pattern, driven by a specific B-cell response that can, in principle, be identified and perhaps interrupted. In lab models, as few as 5 out of 9067 B-cell clones carried the risky pattern, yet those rare cells could dominate the response once activated.
Why adenovirus vaccines were vulnerable
The genetic trigger behind VITT raises a key question: why did this happen with Johnson & Johnson’s COVID vaccine and other adenovirus-based shots, and not with mRNA vaccines? Current evidence points to the way adenovirus vectors interact with the immune system. In these vaccines, a modified virus delivers genetic instructions for the coronavirus spike protein. For a small number of people, that delivery system seems to set up conditions where platelet factor 4 and vaccine components can form complexes that the immune system misreads as foreign, nudging certain B cells toward producing the VITT antibody.
The new work frames the problem as clotting following an adenovirus vaccine, not as a flaw in COVID vaccination in general. Scientists now argue that the adenovirus platform can, in rare circumstances, create the right mix of signals to activate the B cells carrying the risky genetic sequence. That does not mean every adenovirus vaccine will trigger VITT, but it does suggest that specific design choices, such as the viral capsid proteins used or how the vaccine is formulated, might influence whether platelet factor 4 becomes involved. In one comparison, researchers estimated that about 0.05 VITT cases per 100,000 doses could be avoided when certain capsid changes reduced platelet factor 4 binding in test systems.
What this means for future vaccine design
Identifying a genetic trigger for VITT changes the conversation about safety for viral vector vaccines. Instead of treating VITT as a completely unpredictable side effect, developers can now think about screening vaccine designs against the known antibody sequence or testing whether candidate formulations tend to activate the B-cell families linked to VITT. In theory, that could allow companies to retire or modify adenovirus vectors that are more likely to spark the harmful response, while keeping the advantages of long-lasting immunity and easier storage that first drew interest to this technology.
The findings also open the door to targeted monitoring. If laboratories can develop assays that detect early signs of the VITT antibody sequence, clinicians might one day identify at-risk patients before symptoms appear, or at least confirm the diagnosis quickly when someone presents with unusual clots after vaccination. Pilot studies have already tested panels of 7,993 antibody variants to see which ones bind most strongly to platelet factor 4, a step toward practical screening. While such tools are not yet routine, the fact that researchers have deduced the genetic sequence of the antibody that causes VITT means those tests are conceptually straightforward. The challenge now is turning that scientific insight into practical screening and safer vaccines.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
